Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.
2.

Recent developments in public proteomic MS repositories and pipelines.

Mead JA, Bianco L, Bessant C.

Proteomics. 2009 Feb;9(4):861-81. doi: 10.1002/pmic.200800553. Review.

PMID:
19212957
3.

MRMaid, the web-based tool for designing multiple reaction monitoring (MRM) transitions.

Mead JA, Bianco L, Ottone V, Barton C, Kay RG, Lilley KS, Bond NJ, Bessant C.

Mol Cell Proteomics. 2009 Apr;8(4):696-705. doi: 10.1074/mcp.M800192-MCP200. Epub 2008 Nov 15.

4.

Public proteomic MS repositories and pipelines: available tools and biological applications.

Mead JA, Shadforth IP, Bessant C.

Proteomics. 2007 Aug;7(16):2769-86. Review.

PMID:
17654461
5.

Investigation of the metabolic fate of tritiated vincristine in the rat by high-pressure liquid chromatography.

Castle MC, Mead JA.

Biochem Pharmacol. 1978 Jan 1;27(1):37-44. No abstract available.

PMID:
619905
6.

Renal stones and urinary infection: a study of antibiotic treatment.

Chinn RH, Maskell R, Mead JA, Polak A.

Br Med J. 1976 Dec 11;2(6049):1411-3.

7.

Pharmacology of antitumor agents from higher plants.

Sieber SM, Mead JA, Adamson RH.

Cancer Treat Rep. 1976 Aug;60(8):1127-39. Review.

PMID:
136296
9.

Highlighting cancer chemotherapy reports.

Mead JA.

CA Cancer J Clin. 1976 Jan-Feb;26(1):60-1. No abstract available.

10.

Reduction and metabolism of dihydrohomofolate in rhesus monkeys.

Mishra LC, Parmar AS, Mead JA.

Cancer Res. 1974 Dec;34(12):3187-91. No abstract available.

11.
12.

Regeneration of tetrahydrohomofolate in cells. Possible basis for antitumor activity of homofolates.

Mishra LC, Parmar AS, Mead JA.

Biochem Pharmacol. 1974 Jul 1;23(13):1827-34. No abstract available.

PMID:
4458665
13.

Metabolism of tetrahydrohomofolate (NSC 89473) in mice.

Mishra LC, Parmar AS, Mead JA.

Cancer Res. 1974 May;34(5):964-7. No abstract available.

14.

The disposition of the antitumor agent, sangivamycin, in mice.

Hardesty CT, Chaney NA, Waravdekar VS, Mead JA.

Cancer Res. 1974 May;34(5):1005-9. No abstract available.

15.

The effect of folate and folate analogs upon dihydrofolate reductase and DNA synthesis in kidneys of normal mice.

Auletta AE, Gery AM, Parmar A, Davis J, Mishra L, Mead JA.

Life Sci. 1974 Apr 16;14(8):1541-53. No abstract available.

PMID:
4829544
16.
17.

Long-term diuretics and potassium supplements.

Polak A, Down PF, Mead JA.

Lancet. 1972 Dec 16;2(7790):1310-1. No abstract available.

PMID:
4117836
18.

Fate of potassium supplements in six outpatients receiving long-term diuretics for oedematous disease.

Down PF, Polak A, Rao R, Mead JA.

Lancet. 1972 Oct 7;2(7780):721-4. No abstract available.

PMID:
4116141
19.

Baltimore hospital-based group practice.

Mead JA Jr.

Md State Med J. 1972 Oct;21(10):48-9. No abstract available.

PMID:
4666014
20.

The effect of route af administration on the distribution of ellipticine in mice.

Hardesty CT, Chaney NA, Mead JA.

Cancer Res. 1972 Sep;32(9):1884-9. No abstract available.

21.

A method for assessing dihydrofolate reductase inhibition in vivo.

Mishra LC, Parmar AS, Mead JA.

Anal Biochem. 1972 Aug;48(2):515-23. No abstract available.

PMID:
5070045
22.

Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.

DeConti RC, Toftness BR, Agrawal KC, Tomchick R, Mead JA, Bertino JR, Sartorelli AC, Creasey WA.

Cancer Res. 1972 Jul;32(7):1455-62. No abstract available.

23.

The physiological disposition of 14C-labeled 5-hydroxy-pyridine-2-carboxaldehyde thiosemicarbazone (NSC-107,392) in mice.

Tomchick R, Weinstein EP, Mead JA.

Biochem Med. 1972 Jun;6(3):282-93. No abstract available.

PMID:
5041896
24.

The use of dihydrofolate reductase as a signal for scheduling optimal treatment with antileukemic agents.

Hardesty CT, Chen D, Mead JA.

Cancer Res. 1972 Mar;32(3):458-61. No abstract available.

25.

On the biochemical mechanism of action of tetrahydrohomofolic acid.

Mishra LC, Mead JA.

Biochem Pharmacol. 1972 Feb 15;21(4):579-81. No abstract available.

PMID:
5014514
26.

Chemical transformations of tetrahydrohomofolic acid in vitro and in vivo.

Mishra LC, Parmar AS, Mead JA.

Chem Biol Interact. 1972 Jan;4(2):97-102. No abstract available.

PMID:
5058329
27.
28.

Prospects for improved folate antagonists.

Mead JA.

Ann N Y Acad Sci. 1971 Nov 30;186:514-9. No abstract available.

PMID:
5289721
29.

Effect of tetrahydrohomofolate on DNA biosynthesis in leukemic mice.

Mishra LC, Mead JA.

Proc Soc Exp Biol Med. 1971 Nov;138(2):709-11. No abstract available.

PMID:
5118487
30.

Effect of pretreatment with methotrexate on the reduction of dihydrohomofolic acid in mice.

Mishra LC, Parmar AS, Mead JA.

Biochem Pharmacol. 1971 Oct;20(10):2871-8. No abstract available.

PMID:
5114519
31.

Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance.

Schrecker AW, Mead JA, Greenberg NH, Goldin A.

Biochem Pharmacol. 1971 Mar;20(3):716-8. No abstract available.

PMID:
5150168
32.

Increased lifespan of leukemic mice treated with drugs related to (-)-emetine.

Jondorf WR, Abbott BJ, Greenberg NH, Mead JA.

Chemotherapy. 1971;16(2):109-29. No abstract available.

PMID:
5120609
33.

Dihydrofolate reductase activity and loss of resistance in an antifolate-resistant subline of leukemia L1210 after discontinuation of treatment.

Schrecker AW, Mead JA, Greenberg NH, Goldin A.

Chem Biol Interact. 1970 Oct;2(3):229-34. No abstract available.

PMID:
5289825
34.
35.

Distribution studies of tetrahydrohomofolic acid (NSC 89473) in mice.

Mishra LC, Parmar AS, Mead JA.

Cancer Res. 1970 Mar;30(3):642-9. No abstract available.

36.

Enzymatic phosphorylation of sangivamycin.

Hardesty CT, Chaney NA, Waravdekar VS, Mead JA.

Biochim Biophys Acta. 1969 Dec 16;195(2):581-3. No abstract available.

PMID:
5366940
37.

Relationship of structure to antitumor activity in compounds related to folic acid.

Mead JA, Wood HB Jr, Goldin A.

Cancer Chemother Rep 2. 1968 Nov;1(2):273-361. No abstract available.

PMID:
5732302
38.

Potentiation of oral anticoagulant therapy by acetaminophen.

Antlitz AM, Mead JA Jr, Tolentino MA.

Curr Ther Res Clin Exp. 1968 Oct;10(10):501-7. No abstract available.

PMID:
4971464
39.

The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity.

Canellos GP, Mead JA, Greenberg NH, Schrecker AW.

Cancer Res. 1967 Apr;27(4):784-8. No abstract available.

40.

The effect of 3'-iodoaminopterin on dihydrofolate reductase.

Loo TL, Mead JA, Schrecker AW, Shaffer M.

Biochem Pharmacol. 1966 Dec;15(12):2131-3. No abstract available.

PMID:
5973187
41.

Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia.

Mead JA, Goldin A, Kisliuk RL, Friedkin M, Plante L, Crawford EJ, Kwok G.

Cancer Res. 1966 Nov;26(11):2374-9. No abstract available.

42.

Isolation and antileukemic activity, in mice, of 1-beta-D-arabinofuranosylcytosine 5'-phosphate present in synthetic 5'-cytidylic acid.

Schrecker AW, Mead JA, Urshel MJ.

Biochem Pharmacol. 1966 Oct;15(10):1443-52. No abstract available.

PMID:
5971801
43.

The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.

Kline I, Venditti JM, Mead JA, Tyrer DD, Goldin A.

Cancer Res. 1966 May;26(5):848-52. No abstract available.

44.

THE PHARMACOLOGICAL AND BIOCHEMICAL ACTIVITY OF 4-AMINO-4-DEOXY-10-METHYLPTEROYLASPARTIC ACID.

MEAD JA, GREENBERG NH, SCHRECKER AW, SEEGER DR, TOMCUFCIK AS.

Biochem Pharmacol. 1965 Feb;14:105-14. No abstract available.

PMID:
14332455
45.

ANTILEUKEMIC ACTIVITY OF HYDROXYUREA (NSC-32065) AND OTHER UREA DERIVATIVES.

GOLDIN A, VENDITTI JM, MEAD JA, GLYNN JP.

Cancer Chemother Rep. 1964 Aug;40:57-74. No abstract available.

PMID:
14206921
46.

EXPERIMENTS ON DETERMINATION OF MELPHALAN BY FLUORESCENCE. INTERACTION WITH PROTEIN AND VARIOUS SOLUTIONS.

CHIRIGOS MA, MEAD JA.

Anal Biochem. 1964 Mar;7:259-68. No abstract available.

PMID:
14153286
47.

FOLIC ACID ANTAGONIST. EFFECTS ON THE CELL AND THE PATIENT. COMBINED CLINICAL STAFF CONFERENCE AT THE NATIONAL INSTITUTES OF HEALTH.

BERLIN NI, RALL D, MEAD JA, FREIREICH EJ, VANSCOTT E, HERTZ R, LIPSETT MB.

Ann Intern Med. 1963 Dec;59:931-56. No abstract available.

PMID:
14082744
48.

Diabetic acidosis with pancreatic artery thrombosis: unusual complication of carcinoma of the pancreas.

MEAD JA Jr, SMITH VM.

J Am Geriatr Soc. 1963 Apr;11:369-73. No abstract available.

PMID:
13934291
49.

Further observations on the site of action of amethopterin.

CONDIT PT, MEAD JA.

Biochem Pharmacol. 1963 Jan;12:94-6. No abstract available.

PMID:
14022548
50.

Clinical appraisal of pentapiperide methylsulfate a new anticholinergic drug.

SMITH VM, MEAD JA Jr, IDEA BV, MALLARI RP.

Am J Gastroenterol. 1963 Jan;39:52-60. No abstract available.

PMID:
13989590

Supplemental Content

Support Center